Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Johnson

Pediatric Allergy/Immunology Fairfax, VA Medical Doctor

NPI 1285622183 CMS profile 149141

3903A Fair Ridge Dr, Fairfax, VA 22033

Open in the dashboard

General payments

$185,098

844 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$25,400 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Derek Johnson of Fairfax, VA is reported in the CMS Open Payments database as having received $185,098 across 844 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $25,400 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,787 97
2024 General $33,206 119
2023 General $25,512 133
2022 General $31,627 144
2021 General $17,007 107
2020 General $22,944 96
2019 General $30,014 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Johnson
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Derek Johnson were reported at $24,787. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Derek Johnson Pediatric Allergy/Immunology median Middle half National median
2019 $30,014 $325 $92–$1,399 $163
2020 $22,944 $144 $66–$2,490 $114
2021 $17,007 $357 $95–$2,633 $132
2022 $31,627 $385 $125–$2,259 $149
2023 $25,512 $470 $121–$2,946 $160
2024 $33,206 $317 $125–$2,583 $164
2025 $24,787 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $81,989 192 payments
  2. OptiNose US, Inc. $65,491 159 payments
  3. GlaxoSmithKline, LLC. $17,108 91 payments
  4. Genentech, Inc. $4,728 5 payments
  5. Genzyme Corporation $3,855 66 payments
  6. Genentech USA, Inc. $2,937 18 payments
  7. Blueprint Medicines Corporation $1,623 9 payments
  8. Pfizer Inc. $1,397 59 payments
  9. Regeneron Healthcare Solutions, Inc. $1,145 43 payments
  10. ALK-Abello, Inc $745 21 payments
  11. Other $4,082 181 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $118,210 72 payments
  2. Consulting Fee $23,843 13 payments
  3. Food and Beverage $20,086 695 payments
  4. Travel and Lodging $19,200 52 payments
  5. Honoraria $3,544 2 payments
  6. Education $214 10 payments
Products named General payments · program years 2019–2025
  1. Xhance $65,491 159 payments
  2. AIRSUPRA $35,107 49 payments
  3. NUCALA Respiratory $15,727 27 payments
  4. FASENRA Respiratory $15,245 53 payments
  5. FASENRA Respiratory $11,557 24 payments
  6. Xolair $7,664 23 payments
  7. DUPIXENT Immunology $3,507 105 payments
  8. DUPIXENT Inflammation And Immunology $1,008 40 payments
  9. NUCALA Immunology $893 31 payments
  10. Odactra $727 20 payments
  11. Other $9,931 413 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

210

Median for Allergy/ Immunology: 449

Drug cost

$300,730

Median for Allergy/ Immunology: $169,700

Branded share of claims

58.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucala Mepolizumab Brand 11 $141,207
Xolair Omalizumab Brand 23 $71,741
Dupixent Pen Dupilumab Brand 12 $53,039
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $21,078
Alvesco Ciclesonide Brand 17 $10,345
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 13 $1,503
Montelukast Sodium Generic 47 $646
Albuterol Sulfate Hfa Albuterol Sulfate Brand 28 $540
Ipratropium Bromide Generic 11 $419
Omeprazole Generic 17 $113

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$34,060

Medicare's payments for the services billed

Medicare patients

100

Average age 71

Services billed

2,113

65 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 52%
Ischemic heart disease 21%
Osteoporosis 21%
Depression 18%
Chronic kidney disease 17%
Diabetes 16%
COPD 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xhance
$13,678 — —
AIRSUPRA
$13,669 — —
DUPIXENT
$439 12 —
NUCALA
$340 11 —
AYVAKIT
$223 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

844 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record